Mantinex

Memantine Hydrochloride, the active ingredient in Mantinex, is a NMDA receptor antagonist presented as a tablet for oral use. It is indicated for the treatment of moderate to severe Alzheimer’s disease in adult patients.

GNH USA supplies Mantinex as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable access to this antidementia agent for qualified healthcare providers. The company adheres to stringent quality standards and regulatory requirements to ensure product integrity across global markets.

Mantinex, an NMDA receptor antagonist, is employed in the therapeutic management of Alzheimer’s disease, a neurodegenerative disorder characterized by progressive cognitive decline. Clinical trials have demonstrated that memantine can modulate glutamatergic activity, leading to measurable benefits in cognition, behavior, and functional independence. The medication is prescribed after careful assessment of disease severity and patient suitability, often in combination with cholinesterase inhibitors.

- Alzheimer’s disease (moderate to severe): improves cognitive function, daily living activities, and overall clinical status in affected patients.

Common Side Effects: - Dizziness: mild to moderate sensation of light‑headedness. - Headache: transient cranial discomfort. - Constipation: reduced bowel movements. - Fatigue: feeling of tiredness or reduced energy. - Confusion: occasional disorientation. - Hypertension: mild increase in blood pressure.

Serious or Rare Side Effects: - Seizures: convulsive episodes requiring medical attention. - Severe allergic reaction: rash, swelling, or difficulty breathing. - Hallucinations: visual or auditory disturbances. - Cardiac arrhythmia: irregular heart rhythm.

Mantinex should be used with caution in patients with the following considerations: - Renal impairment: assess kidney function and adjust therapy as needed. - History of seizures: monitor for increased seizure activity. - Cardiovascular disease: evaluate risk before initiating therapy. - Concurrent use of other NMDA antagonists: avoid combined use. - Pregnancy and lactation: safety not established; weigh potential benefits against risks. - Store at ambient temperature: keep in the original pack, protect from moisture and direct sunlight.

Mantinex may interact with several medicines. Review the following categories:

Major Interactions (Avoid): - Amantadine: increased risk of neurotoxicity. - Ketamine: additive NMDA antagonism leading to excessive CNS depression. - Mannitol: may reduce oral absorption of memantine.

Moderate Interactions (Monitor Closely): - Anticholinesterase inhibitors: potential reduction in therapeutic effect. - Central nervous system depressants: enhanced sedation or drowsiness. - Diuretics: possible alteration of plasma memantine concentrations.